40 completed, 17 terminated, 8 unknown, 7 withdrawn. 80 Phase 2, 13 Phase 1, 1 Phase 3.
Follow Arsenic Trioxide: new trials by email Literature Review of Arsenic Trioxide trials Research Report on Arsenic Trioxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arsenic Trioxide Combined With Chemotherapy for Relapsed SHH-Activated and/or TP53-Mutant Medulloblastoma Arsenic Trioxide (ATO), ETOPOSIDE - Study, Cisplatin - Medulloblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 78 | 2026-10-01 | 2026-10-02 |
| Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma Arsenic trioxide, MAPK inhibitors, Chemotherapy - Neuroblastoma | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 92 | 2025-05-01 | 2025-04-18 |
| Oral-ATO for TP53-mutated Myeloid Malignancies Oral arsenic trioxide - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Recruiting | The University of Hong Kong | 30 | 2025-02-07 | 2025-06-10 |
| Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer Arsenic trioxide - Pediatric Cancer, Li-Fraumeni Syndrome | Phase 2 | Recruiting | Yang Li | 50 | 2023-12-13 | 2024-01-03 |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation Arsenic trioxide - Refractory Solid Tumors | Phase 2 | Unknown | Ruijin Hospital | 20 | 2021-04-20 | 2021-05-13 |
| Arsenic Trioxide for Structural p53 Mutations Arsenic Trioxide - Arsenic Trioxide, p53 Mutations | Phase 2 | Unknown | Shanghai Changzheng Hospital | 30 | 2021-01-01 | 2021-01-06 |
| Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Mylotarg, Arsenic Trioxide, All-trans retinoic acid - Acute Promyelocytic Leukemia | Phase 2 | Recruiting | Associazione Italiana Ematologia Oncologia Pediatrica | 89 | 2019-10-09 | 2024-04-15 |
| Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Oral arsenic Trioxide, ATRA and ascorbic acid - Acute Promyelocytic Leukemia | Phase 2 | Unknown | The University of Hong Kong | 60 | 2018-08-15 | 2022-10-04 |
| Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations Decitabine, Arsenic Trioxide, Cytarabine - Acute Myeloid Leukemia, P53 Mutation | Phase 2 | Unknown | Li Junmin | 100 | 2018-03-01 | 2018-01-04 |
| Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma Arsenic Trioxide - Neuroblastoma | Phase 2 | Active not recruiting | Yang Li | 80 | 2017-06-12 | 2025-05-21 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia Cytarabine, all-trans retinoic acid, Arsenic Trioxide - AML | Phase 1 / Phase 2 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2017-02-08 | 2025-05-30 |
| Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide Arsenic Trioxide Injectable Solution - Chronic Graft-Versus-Host Disease, Immune System Diseases | Phase 2 | Completed | Medsenic | 21 | 2016-12-01 | 2022-05-09 |
| Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients TACE, Arsenic trioxide - Primary Hepatocellular Carcinoma | Phase 2 | Unknown | Hunan Provincial People's Hospital | 190 | 2016-11-01 | 2017-02-23 |
| Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) Arsenic trioxide - Systemic Lupus | Phase 2 | Terminated | Nantes University Hospital | 11 | 2013-07-01 | 2016-01-06 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia arsenic trioxide, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Withdrawn | Stanford University | 2013-05-01 | 2018-05-21 | |
| Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS Decitabine, Carboplatin, Arsenic trioxide - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Completed | Fox Chase Cancer Center | 92 | 2013-04-01 | 2021-05-19 |
| Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma arsenic trioxide - Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer | Phase 1 / Phase 2 | Completed | Stanford University | 5 | 2013-04-01 | 2018-06-08 |
| Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Arsenic Trioxide, Gemtuzumab Ozogamicin, Laboratory Biomarker Analysis - Acute Promyelocytic Leukemia With PML-RARA | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 151 | 2011-10-05 | 2026-05-20 |
| Study of Arsenic Trioxide in Small Cell Lung Cancer Arsenic Trioxide - Lung Cancer, Cancer of Lung | Phase 2 | Completed | Emory University | 20 | 2011-08-01 | 2021-02-17 |
Showing 20 of 80. Sign in to see all of them.
Leukemia (23) · Myelodysplastic Syndromes (14) · Leukemia, Promyelocytic, Acute (12) · Multiple Myeloma (12) · Leukemia, Myeloid, Acute (11) · Neoplasms, Plasma Cell (9) · Leukemia, Myelomonocytic, Chronic (8) · Anemia, Refractory, with Excess of Blasts (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Blast Crisis (5) · Leukemia, Monocytic, Acute (4) · Lymphoma (4) · Myelodysplastic-Myeloproliferative Diseases (4) · Myeloproliferative Disorders (4) · Burkitt Lymphoma (3)
Memorial Sloan Kettering Cancer Center (9) · M.D. Anderson Cancer Center (6) · CTI BioPharma (3) · Northwestern University (3) · The University of Texas Medical Branch, Galveston (3) · National Cancer Institute (NCI) (2) · OHSU Knight Cancer Institute (2) · SCRI Development Innovations, LLC (2) · SWOG Cancer Research Network (2) · Stanford University (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · The Cleveland Clinic (2) · The University of Hong Kong (2) · University of Southern California (2) · Washington University School of Medicine (2)
United States (58) · China (9) · France (2) · Hong Kong (2) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Iran (1) · Ireland (1) · Israel (1) · Italy (1) · Mexico (1) · Netherlands (1)
Dan Douer, MD (2) · Deborah A. Thomas, MD (2) · Dennie V. Jones, MD (2) · John D. Hainsworth, MD (2) · Joseph G. Jurcic, MD (2) · Martin S. Tallman, MD (2) · Mikkael A. Sekeres, MD, MS (2) · Muzaffar H. Qazilbash, MD (2) · Scott C. Stromatt, MD (2) · Yang Li, Professor (2) · Alan K. Burnett, MD, FRCP (1) · Aleksandra Simic, MD (1) · Anne Huyhn, Dr (1) · Avi B. Markowitz, MD (1) · Bart L. Scott, MD (1)
PMID 35417717, PMID 12473574, PMID 16651647, PMID 16688776, PMID 16870552, PMID 18082257, PMID 26440706, PMID 27142472, PMID 32330241, PMID 33658052, PMID 35830931, PMID 39584789, PMID 40453133
P30CA008748 (2), 2017 (1), K23CA164015 (1), N01CM17003 (1), P30CA006973 (1), P30CA043703 (1), P30CA069533 (1), U10CA031946 (1), U10CA032102 (1)